Andrew M. Callos

Executive Vice President, Chief Commercial OfficeratCytokinetics· In proxies 2021–2025

Pay in FY2025-14% from the year before · Cytokinetics stock +35.1% the same year

Andrew M. Callos was paid $3.8M in FY2025 (Dec), down 14%. Cytokinetics stock rose 35.1% that year.

Pay$100 in the stock at the end of FY20 → $306

Pay is from the Summary Compensation Table of each Cytokinetics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

CYTK
CytokineticsPublic company · 5 yr
- Executive Vice President, Chief Commercial Officer2021 – Present · 5 yrStock in role +193%

Roles come from the proxy statements of each company.

Activity

Pay
Cytokinetics Division head pay fell 14% to $3.8M. The stock rose 35% in FY2025 (Dec).
DEF 14AApr 17, 2026
Pay
Cytokinetics Division head pay rose 37% to $4.4M. The stock fell 44% in FY2024 (Dec).
DEF 14AApr 10, 2025
Pay
Cytokinetics Division head pay fell 23% to $2.6M. The stock rose 1% in FY2022 (Dec).
DEF 14AApr 10, 2025
Pay
Cytokinetics Division head pay rose 25% to $3.2M. The stock rose 82% in FY2023 (Dec).
DEF 14AApr 8, 2024

For the press:Download CSV Download PNG How to use our data

Two people shown as one, or a wrong number?